



| | | | | | |
|--|--|---|--|----------------------------|--------------------------|
| FORM PTO-1449 | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P1824R1 | Serial No. 10/099,818 |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | | Applicant Iqbal Grewal | |
| | | | | Filing Date 14 Mar 2002 | Group 1644 |



| U.S. PATENT DOCUMENTS | | | | | | | |
|--|-----------------|--|----------|-------------------------|---|--|--|
| Examiner Initials | Document Number | Date | Name | Class | Subclass | Filing Date | |
| No | 1 | 2002/0058029 | 16.05.02 | Hanna | <div style="transform: rotate(-45deg); font-size: 2em; font-weight: bold;">RECEIVED</div> | <div style="transform: rotate(-45deg); font-size: 1.5em; font-weight: bold;">NOV 07 2002</div> | <div style="transform: rotate(-45deg); font-size: 1.5em; font-weight: bold;">TECH CENTER 1800/2900</div> |
| | 2 | 2002/0106371 | 08.08.02 | Boer et al. | | | |
| | 3 | 2002/0142358 | 03.10.02 | Mikayama et al. | | | |
| | 4 | 5,182,368 | 26.01.93 | Ledbetter et al. | | | |
| | 5 | 5,247,069 | 21.09.93 | Ledbetter et al. | | | |
| | 6 | 5,674,492 | 07.10.97 | Armitage et al. | | | |
| | 7 | 5,677,165 | 14.10.97 | de Boer et al. | | | |
| | 8 | 5,736,137 | 07.04.98 | Anderson et al. | | | |
| | 9 | 5,786,456 | 28.07.98 | Ledbetter, J. A. et al. | | | |
| | 10 | 5,849,898 | 15.12.98 | Seed et al. | | | |
| | 11 | 5,869,050 | 09.02.99 | de Boer et al. | | | |
| | 12 | 5,874,082 | 23.02.99 | de Boer | | | |
| | 13 | 5,961,974 | 05.10.99 | Armitage et al. | | | |
| | 14 | 6,004,552 | 21.12.99 | de Boer et al. | | | |
| | 15 | 6,056,959 | 02.05.00 | de Boer et al. | | | |
| | 16 | 6,413,514 | 02.07.02 | Aruffo et al. | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| Examiner Initials | Document Number | Date | Country | Class | Subclass | Translation Yes No | |
| | 17 | 806,963 | 19.11.97 | EP | <div style="transform: rotate(-45deg); font-size: 2em; font-weight: bold;">X</div> | | |
| | 18 | WO 00/75348 | 14.12.00 | PCT | | | |
| | 19 | WO 01/37870 | 31.05.01 | PCT | | | |
| | 20 | WO 88/06891 | 22.09.88 | PCT | | | |
| | 21 | WO 95/17202 | 29.06.95 | PCT | | | |
| | 22 | WO 96/18413 | 20.06.96 | PCT | | | |
| | 23 | WO 97/31025 | 28.08.97 | PCT | | | |
| | 24 | WO 97/34633 | 25.09.97 | PCT | | | |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | |
| | 25 | Anderson et al., "Expression of Human B Cell-Associated Antigens on Leukemias and Lymphomas: A Model of Human B Cell Differentiation." <u>Blood</u> 63(6):1424-1433 (1984) | | | | | |
| | 26 | Ashwell et al., "T-Cell Tumor Elimination as a Result of T-Cell Receptor-Mediated Activation." <u>Science</u> , 237:61-64 (Jul 1987) | | | | | |
| | 27 | Beckwith et al., "Phorbol Ester-Induced, Cell-Cycle-Specific, Growth Inhibition of Human B-Lymphoma Cell Lines." <u>J. Natl. Cancer Institute</u> 82(6):501-509 (Mar 1990) | | | | | |
| | 28 | Bridges et al., "Selective In Vivo Antitumor Effects of Monoclonal Anti-Y-A Antibody on B Cell Lymphoma." <u>J. Immunol.</u> 139(12):4242-4249 (Dec 1987) | | | | | |
| | 29 | Demidem et al., "Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs." <u>Cancer Biotherapy & Radiopharmaceuticals</u> 12(3):177-186 (1997) | | | | | |
| Examiner <i>Philip G. Anderson 11/28/05</i> | | | | Date Considered | | | |

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1824R1

Serial No.

10/099,818

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Iqbal Grewal

Filing Date

14 Mar 2002

Group

1644

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

| | |
|----|--|
| 30 | Edwards and Cambridge., "Sustained Improvement in Rheumatoid Arthritis Following a Protocol Designed to Deplete B Lymphocytes." <u>Rheumatology</u> , 40:205-211 (2001) |
| 31 | Einfeld et al., "Molecular Cloning of the Human B Cell CD20 Receptor Predicts a Hydrophobic Protein with Multiple Transmembrane Domains." <u>EMBO Journal</u> 7(3):711-717 (1988) |
| 32 | Fanslow et al., "White Cell Differentiation Antigens." <u>Leukocyte Typing V</u> , (Proceedings of the Fifth International Workshop & Conf. Held in Boston, USA November 1993), Schlossman et al., eds. Vol. 1:555-556 (1995) |
| 33 | Francisco et al., "Construction, Expression, and Characterization of BD1-G28-5 sFv, A Single-Chain Anti-CD40 Immunotoxin Containing the Ribosome-Inactivating Protein Bryodin 1." <u>J. Bio. Chem.</u> 272(39):24165-24169 (Sep 1997) |
| 34 | Punakoshi et al., "Inhibition of Human B-Cell Lymphoma Growth by CD40 Stimulation." <u>Blood</u> , 83(10):2787-2794 (May 1994) |
| 35 | Katira et al., "White Cell Differentiation Antigens." <u>Leukocyte Typing V</u> , (Proceedings of the Fifth Internat. Workshop & Conf. Held in Boston, USA, November 1993), Schlossman et al, eds. Vol. 1:547-550 (1995) |
| 36 | Kehry., "CD40-Mediated Signaling in B Cells Balancing Cell Survival, Growth and Death." <u>J. Immunol.</u> 156:2345-2348 (1996) |
| 37 | Kuhne et al., "Assembly and Regulation of the CD40 Receptor Complex in Human B Cells." <u>Journal of Experimental Medicine</u> , 186:337-342 (Jul 1997) |
| 38 | Maloney et al., "The Anti-Tumor Effect of Monoclonal Anti-CD20 Antibody (mAb) Therapy Includes Direct Anti-Proliferative Activity and Induction of Apoptosis in CD20 Positive Non-Hodgkin's Lymphoma (nhl) Cell Lines." <u>Blood</u> , (Abstract #2535) 88(10):637a (1996) |
| 39 | Page and DeFranco., "Role of Phosphoinositide-Derived Second Messengers in Mediating Anti-IgM-Induced Growth Arrest of WEHI-231 B Lymphoma Cells." <u>J. Immunol.</u> 140(11):3717-3726 (Jun 1988) |
| 40 | Pellat-Deceunynck et al., "Expression of CD28 and CD40 in Human Myeloma Cells: A Comparative Study with Normal Plasma Cells." <u>Blood</u> , 84(8):2597-2603 (Oct 1994) |
| 41 | Protheroe et al., "Remission of Inflammatory Arthropathy in Association with Anti-CD20 Therapy for Non-Hodgkin's Lymphoma." <u>Rheumatology (Oxford)</u> , 38(11):1150-1152 (Nov 1999) |
| 42 | Reff et al., "Depletion of B Cells In Vivo by a Chimeric Mouse Human Monoclonal Antibody to CD20." <u>Blood</u> , 83(2):435-445 (Jan 15, 1994) |
| 43 | Speiser et al., "A Regulatory Role for TRAF1 in Antigen-Induced Apoptosis of T Cells." <u>Journal of Experimental Medicine</u> 185:1777-1783 (May 1997) |
| 44 | Tedder et al., "The B Cell Surface Molecule B1 is Functionally Linked with B Cell Activation and Differentiation." <u>The Journal of Immunology</u> , 135(2):973-979 (1985) |
| 45 | Tedder et al., "The CD20 Surface Molecule of B Lymphocytes Functions as a Calcium Channel." <u>J. Cell. Biochem.</u> (Abstract # M 023) 14D:195 (1990) |
| 46 | Uckun et al., "Temporal Association of CD40 Antigen Expression with Discrete Stages of Human B-Cell Ontogeny and the Efficacy of Anti-CD40 Immunotoxins Against Clonogenic B-Lineage Acute Lymphoblastic Leukemia as well as B-Lineage Non-Hodgkin's Lymphoma Cells." <u>Blood</u> , 76:2449-2456 (Dec 1990) |
| 47 | Valentine et al., "Phosphorylation of the CD20 Phosphoprotein in Resting B Lymphocytes." <u>J. Bio. Chem.</u> 264(19):11282-11287 (Jul 5, 1989) |
| 48 | Yeh et al., "Early Lethality, Functional NF- κ B Activation, and Increased Sensitivity to TNF-Induced Cell Death in TRAF2-Deficient Mice." <u>Immunity</u> , 7:715-725 (Nov 1997) |

Examiner

Punup/Grewal 4/22/05

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

NOV 07 2002

TECH CENTER 1600/2900

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1824R1

Serial No.

10/099,818

LIST OF DISCLOSURES OTHER THAN APPLICANT

(Use several sheets if necessary)

Applicant

Iqbal Grewal

Filing Date

14 Mar 2002

Group

1644

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- | | |
|----|--|
| 49 | Yllidge et al., "Radioimmunotherapy in the π -BCL ₁ B Cell Lymphoma Model: Efficacy Depends on More Than Targeted Irradiation Alone" <u>Cancer Biotherapy & Radiopharm.</u> 15(6):581-591 (2000) |
| 50 | Jakobson et al., "Agonistic Properties of Anti-B Cell Antibodies Purified on Staphylococcal Protein A May be Due to Contaminating Protein A" <u>J. Immunological Methods</u> 152:49-57 (1992) |
| 51 | Maloney et al., "IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patients with Relapsed Non-Hodgkin's Lymphoma" <u>J. Clin. Oncol.</u> 15(10):3266-3274 (Oct 1997) |
| 52 | Murphy et al., "Antibodies to CD40 Prevent Epstein-Barr Virus-Mediated Human B-Cell Lymphomagenesis in Severe Combined Immune Deficient Mice Given Human Peripheral Blood Lymphocytes" <u>Blood</u> 86(5):1946-1953 (Sep 1995) |
| 53 | Ottaviano et al., "CD40 Activation as Potential Tool in Malignant Neoplasms" <u>Tumori</u> 88:361-366 (2002) |
| 54 | Ye et al., "Augmentation of a Humanized Anti-HER2 mAb 4D5 Induced Growth Inhibition by a Human-Mouse Chimeric Anti-EGF Receptor mAb C225" <u>Oncogene</u> 18:731-738 (1999) |
| 55 | Zhou et al., "An Agonist Anti-Human CD40 Monoclonal Antibody that Induces Dendritic Cell Formation and Maturation and Inhibits Proliferation of a Myeloma Cell Line" <u>Hybridoma</u> 18(6):471-478 (1999) |
| 56 | Ziebold et al., "Differential Effects of CD40 Stimulation on Normal and Neoplastic Cell Growth" <u>Archivum Immunologiae et Thera. Experim.</u> 48:225-233 (2000) |

RECEIVED
APR 23 2003
TECH CENTER 1600/2900

Examiner

Pamela G. Grewal 11/28/05

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Group
1614

USCOMM-DC 80-398.